Intravenous Immunoglobulin (IVIG) in the Treatment of Small Fiber Neuropathy Due to TS-HDS, FGFR-3, or Plexin D1 Antibodies: a Double Blinded Placebo-controlled Phase II Trial

This study will enroll patients with small fiber neuropathy (SFN). The study will look at an intravenous immunoglobulin (IVIG) called Panzyga. Panzyga is approved by the FDA as a therapy for Primary humoral immunodeficiency (PI) in patients 2 years of age and older; Chronic immune thrombocytopenia (ITP) in adults and Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. It has not been approved by the FDA for use in SFN.
There is mounting evidence that Intravenous Immunoglobulin (IVIG) can cause pain reduction and improve objective nerve fiber densities on skin biopsies in great numbers in SFN patients. The primary outcome is quantified improvement in intraepidermal nerve fiber density (IENFD) on repeat skin punch biopsy after 6 months of IVIG treatment.

Start Date15 Dec 2023

Sponsor / Collaborator

Henry Ford Health System

[+1]

NCT04929236

/ RecruitingPhase 3

Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Start Date01 Oct 2023

Sponsor / Collaborator

Octapharma AG

NCT04354129

/ Active, not recruitingNot ApplicableIIT

Safety, Tolerability, and Patient Satisfaction of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment by Rapid Push in Patients With Primary or Secondary Immunodeficiency (PID or SID)

This study will assess the relative safety, tolerability, and participant satisfaction in participants using the rapid manual push method with Cutaquig®. The hypothesis being that treatment with Cutaquig® by rapid manual push method will improve the safety, tolerability and patient satisfaction of participants with PID or SID.
Cutaquig® by rapid push is already approved in Canada and has proven to be efficacious in preventing significant infection. However, relative safety, tolerability, and patient satisfaction have not been studied in these patients. The information gained from this study will improve the safety and tolerability knowledge database and will support the optimal use of Cutaquig® - thus benefitting both physicians and patients.

Start Date01 Apr 2023

Sponsor / Collaborator

University of Alberta

[+1]

100 Clinical Results associated with Immune Globulin Intravenous (Human) (Octapharma)

100 Translational Medicine associated with Immune Globulin Intravenous (Human) (Octapharma)

100 Patents (Medical) associated with Immune Globulin Intravenous (Human) (Octapharma)

738

Literatures (Medical) associated with Immune Globulin Intravenous (Human) (Octapharma)

01 Jun 2025·BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY

Considerations and approaches for early onset fetal anemia due to red cell alloimmunization

Review

Author: Moise, Kenneth J

There is no widely accepted definition for early onset hemolytic disease of the fetus and newborn (EOS-HDFN). Several reported series of patients managed with intravascular intrauterine transfusions (IVT's) prior to 20-22 weeks' gestation have been associated with a perinatal mortality of 20 %. It would therefore seem appropriate to define EOS-HDFN as a fetal demise, hydrops fetalis or the need for intrauterine transfusion for suspected fetal anemia prior to 20-22 weeks' gestation. Evaluation of the patient in her next pregnancy with EOS-HDFN history should include a free fetal DNA analysis at 10-12 weeks' gestation to confirm the at-risk fetus. Weekly middle cerebral artery peak systolic velocity determinations using Doppler ultrasound should be initiated by 15 weeks' gestation. Immunomodulation with intravenous immune globulin with or without plasmapheresis should be considered as early at 10-12 weeks' gestation. If IUT's are required prior to 20 weeks' gestation, an intraperitoneal approach can be used until a more advanced gestation can be attained when intravascular fetal access is possible. In the near future, neonatal Fc receptor blockade with a monoclonal antibody may supplant invasive IUT's in the treatment of EOS-HDFN.

01 Jun 2025·American journal of ophthalmology case reports

A seven-year electroretinography follow-up of a patient with melanoma-associated retinopathy stabilized on pembrolizumab treatment

Article

Author: Tshuva-Bitton, Raz ; Rotenstreich, Ygal ; Agmon-Levin, Nancy ; Sher, Ifat ; Ostrovsky, Michael ; Vishnevskia-Dai, Vicktoria

Purpose:

Melanoma-associated retinopathy (MAR) is a rare, auto-immune paraneoplastic syndrome associated with metastatic melanoma. Over the last decade, patient survival has improved dramatically, mainly due to the development of immunotherapy. However, data on long-term MAR patient follow-up and response to modern standard-of-care treatment are lacking. This single-patient case report presents a seven-year, multimodal follow-up of a young MAR patient treated with immune-checkpoint inhibitors.

Observations:

A 46-year-old Israeli male with a history of cutaneous malignant melanoma presented with sudden onset of bilateral shimmering, flickering, and nyctalopia a year and a half after diagnosis. Shortly thereafter, new subcarinal metastasis was observed on Positron Emission Tomography-Computed Tomography. Significantly reduced electroretinography (ERG) a- and b-wave responses led to a diagnosis of MAR, later confirmed by high titers of autoantibodies against retinal bipolar cells. Half a year later, macular thinning, particularly within the inner nuclear and inner plexiform layers of the outer macular ring, with no substantial change in the outer retina, was observed on optical coherence tomography (OCT). A treatment regimen combining intravenous immune globulin, azathioprine, and prednisone allowed partial steroid tapering over the following 2.5 years but showed substantial toxicity and a lack of significant improvement on OCT and ERG. Pembrolizumab treatment was initiated following metastatic progression and resulted in stabilization of the patient's primary oncologic disease, as well as an increase in macular thickness and enhanced retinal function with an increase of over 60 % in dark adapted (DA) b-wave response over the following year.

Conclusions and importance:

MAR may be the first sign of systemic metastatic melanoma, thus warranting a high degree of clinical suspicion. While OCT and ERG showed mostly concordant results over the patient's follow-up, ERG proved to be a more sensitive tool for the early diagnosis of MAR. Early immunotherapy treatment should be considered in antibody-positive MAR patients.

01 Apr 2025·TRANSFUSION

Intravenous immune globulin and risk factors for adverse events in the pediatric population: Considering ABO and secretor status

Letter

Author: Binns, Thomas C. ; Woo, Jennifer S. ; Booth, Garrett S. ; Jacobs, Jeremy W. ; Adkins, Brian D.

News (Medical) associated with Immune Globulin Intravenous (Human) (Octapharma)

28 May 2025

·www.prnewswire.com

Octapharma Releases Results for Phase 3 Superiority Study of Pediatric Acute-onset Neuropsychiatric Syndrome

Clinical Global Impression Data Showed Statistically Significant & Clinically Relevant Improvement in Pediatric PANS Patients PARAMUS, N.J., May 28, 2025 /PRNewswire/ -- Octapharma has released the results from its prospective, randomized, double-blind, parallel group, crossover, placebo-controlled phase 3 study comparing the effectiveness of PANZYGA® (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS). Continue Reading The CY-BOCS score (Children's Yale-Brown Obsessive-Compulsive Scale) measured at 9 weeks was utilized as the primary endpoint for assessing PANZYGA® effectiveness in reducing the severity of PANS symptoms. In addition, other secondary endpoints such as the Clinical Global Impression (CGI-I) were also measured. The endpoints were measured at week 9 and week 18. Study results suggest that PANZYGA® may address the broader disease burden in pediatric neuropsychiatric syndromes Post this From baseline (week 0) to week 9, there was a mean improvement of 31.1% (SD 40.68) in the PANZYGA® group CY-BOCS score as compared to 12.1% (SD 68.39) in the placebo group. Researchers compared the CY-BOCS score of the participants in the two groups as a ratio at week 9 and week 0 (CY-BOCS score at week 9/CY-BOCS score at week 0). While the mean ratio of the total CY-BOCS score at week 9 improved in the PANZYGA® group as compared to the placebo group (primary endpoint), the ratio difference between the two groups was not statistically significant with a probability-value (p-value) of 0.072. The research team also observed that the difference in the Improvement of the Clinical Global Impression (CGI-I) score at week 9 (secondary endpoint) was statistically significant between both groups with a higher improvement in the IVIG group (p-value = 0.017). Please visit euclinicaltrials.eu for the study data. The study utilized a crossover analysis from week 9 to week 18 where the PANZYGA® group participants received the placebo and the participants who had received the placebo until week 9 were given PANZYGA® through week 18. Researchers observed the mean total CY-BOCS score in both treatment arms continued to improve. The CY-BOCS score improvement was more prominent in the participant group that initially received PANZYGA® until week 9, which researchers attributed to a continued response to the PANZYGA® treatment in the first half of the study. "While this Phase III trial did not meet its primary efficacy outcome of OCD symptom improvement measured by CY-BOCS, it revealed promising insights: the key secondary endpoint of Clinical Global Impression (CGI) showed statistically significant and clinically relevant improvement," said Principal Investigator Michael Daines, M.D., Division Chief of Pediatric Allergy and Immunology at the University of Arizona College of Medicine. "CGI reflects the holistic impact of PANS/PANDAS on a patient's life, encompassing behavioral, cognitive, and physical symptoms. These results suggest that PANZYGA® may address the broader disease burden in pediatric acute-onset neuropsychiatric syndromes, offering a potential therapeutic pathway for families navigating this complex condition. Further research into this investigational use of PANZYGA® is needed to confirm this suggestion." The PACE Foundation, along with fellow advocacy groups, is proud to have supported recruitment for this important trial. "We're grateful to Octapharma for their compassion and ongoing commitment to families affected by this challenging disease," said Paul Ryan, PACE Foundation Co-Founder and President. A Challenging Disease for Families & Providers PANS is diagnosed in children who experience sudden dramatic, often overnight, onset of obsessive-compulsive symptoms and/or severe eating restrictions, along with at least two other cognitive, behavioral, or neurological symptoms. Brain inflammation can occur when the body's immune system mistakenly attacks healthy brain cells. "PANS is a very challenging disease for the medical community and families," said Octapharma USA President Flemming Nielsen. "Parents are confronted with the challenge of seeing their children afflicted with sudden-onset, debilitating, and difficult to treat OCD as well as other behavioral and cognitive issues. Octapharma looks forward to bringing relief to children and their families." Octapharma enrolled 71 patients from age 6 to 17 with a confirmed diagnosis of moderate to severe PANS in the prospective, randomized, double-blind, parallel group, placebo-controlled superiority study. (ClinicalTrials.gov Identifier: NCT04508530). Participants received three infusions of PANZYGA® or placebo over two days every three weeks for a total of nine weeks, with an additional double-blind, crossover safety and efficacy follow-up phase of three infusions of PANZYGA® or placebo administered over two days every three weeks for a total of nine weeks. The primary objective of the study was to assess whether PANZYGA® is superior to placebo (0.9% w/v sodium chloride) for reducing the severity of symptoms associated with PANS in pediatric patients. The secondary objectives were to evaluate the sustainability of the reduction of the severity of symptoms in pediatric patients treated with PANZYGA®; and assess the efficacy of PANZYGA® treatment in reducing functional impairment associated with PANS. About PANZYGA ® PANZYGA® is an immune globulin intravenous, (human) - ifas 10% liquid preparation indicated for: - Primary humoral immunodeficiency (PI) in patients 2 years of age and older; - Chronic immune thrombocytopenia (ITP) in adults; and - Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE – Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA®. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. – Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA® does not contain sucrose. – For patients at risk of thrombosis, renal dysfunction, or renal failure, administer PANZYGA® at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Please see full prescribing information at hcp.panzygausa.com/pi. About Octapharma Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 employees worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Hematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centers across Europe and the US. Octapharma has over 40 years of experience in patient care. The company's American subsidiary, Octapharma USA, is located in Paramus, N.J. For more information, please visit octapharmausa.com. PANZ-0850 SOURCE Octapharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3

15 Nov 2024

·www.echemi.com

Pfizer Plans to Sell Hospital Drug Division, 35% of Chinese Market to Change Hands

On November 12, Reuters reported that US pharmaceutical giant Pfizer plans to sell its hospital drugs unit and is currently working with Goldman Sachs to evaluate it. The move means that the products, including antibiotics, steroids and immunoglobulins, will change owners, including the original drug Supraxen, which has a 35 percent market share in China. Pfizer's hospital drugs unit is an asset it acquired after acquiring Hospira for $17 billion in 2015. Less than a decade later, however, Pfizer was willing to put it up for sale, and it is interesting why. It is speculated that the pressure behind this decision may come from investment institutions. The Starboard Value fund made a strategic investment in Pfizer this year, and according to data from the Wall Street Journal, it now holds a $1 billion stake in the company, enough to influence Pfizer's management decisions. Starboard's chief financial officer has repeatedly called on Pfizer to optimize internal capital allocation, liquidate some of its assets and put more money into areas with more potential. Pfizer's hospital pharmaceuticals division includes anti-infective drugs and sterile injections, including well-known antibiotics Supraxen, Sfortol and Zithromax, steroids Medrol and immunoglobulin product Panzyga, and is currently part of its specialty pharmaceuticals business. In 2023, the division contributed billions of dollars in revenue to Pfizer and maintained a 15% growth rate. However, from the perspective of the capital market, such a growth rate still seems to fall short of expectations. Pfizer is widely expected to make further changes to its business segments in the future. Under the significant impact of the Starboard Value fund on Pfizer's strategic layout, Pfizer's core business may also face significant changes, which adds a considerable degree of uncertainty to the company's future development. On November 13, Pfizer's share price was slightly affected, falling nearly 3% at one point.

Acquisition

01 Nov 2023

·www.fiercehealthcare.com

CMS finalizes $140M increase to home health payments

CMS released an unpublished rule Wednesday that includes increasing CY 2024 home health payments by 0.8%. Centers for Medicare & Medicaid Services (CMS) released a rule Wednesday that increases the 2024 home health payments by 0.8%, or $140 million. “The $140 million increase in estimated payments for CY 2024 reflects the effects of the CY 2024 home health payment update percentage of 3% ($525 million increase), an estimated 2.6% decrease that reflects the effects of the permanent behavioral assumption adjustment ($455 million) and an estimated 0.4% increase that reflects the effects of an updated FDL ($70 million increase),” the unpublished rule said. CMS expects increasing the rate will bring home health payments in line with statutory payment authority. In July, the Biden administration proposed cutting reimbursements to home health providers by 2.2% next year, or an estimated $375 million less than 2023 payment levels. It also proposed cutting home health rates by 5.1% or $460 million. Instead, CMS is finalizing a -2.89% adjustment, just half of the proposed home health cut earlier in the year, acknowledging that 5.1% could’ve been “too burdensome” a cut for many providers. The proposed rule will be published in the Federal Register Nov. 13, effective Jan. 1, 2024. Several home health advocacy groups criticized the final rule's implications on systems around the country. "The Partnership for Quality Home Healthcare is extremely disappointed that the Centers for Medicare & Medicaid Services (CMS) finalized a -2.89% cut to home health in its CY2024 Home Health Prospective Payment System (HH PPS) Final Rule," said the Partnership in a statement to Fierce Healthcare. "On top of last year’s nearly -4% cut, CMS’s decision to only partially mitigate their proposed cut to home health will cause further harm to patient access and create financial instability that will make it harder to provide care in the home." "Both patients and providers have described how difficult it already is to access and deliver home health services because of years of continuous Medicare cuts, a significant staffing shortage, and rising inflation," said CEO Joanne Cunningham. "I do not understand what the disconnect is. With labor and inflation costs continuing to rise dramatically and home health providers dealing with a national healthcare workforce crisis, any cut to home health will cause further harm. To put these numbers into context, the rule finalizes a base rate year-over-year increase of less than $1 per day to care for Medicare’s sickest patients. And while CMS is slightly delaying implementation of the permanent cut for next year, those dollars will be cut from home health in future years.” The Partnership stated that it shared both quantitative and anecdotal data with CMS showing that patients are struggling with access, and that these changes would result in more access problems. Cunningham called on lawmakers to block cuts to home health. “We continue to strenuously disagree with CMS’ rate setting actions, including the budget neutrality methodology that CMS employed to arrive at the rate adjustments,” NAHC President William A. Dombi told Home Health Care News. “We recognize that CMS has reduced the proposed 2024 rate cut. However, overall spending on Medicare home health is down, 500,000 fewer patients are receiving care annually since 2018, patient referrals are being rejected more than 50% of the time because providers cannot afford to provide the care needed within the payment rates, and providers have closed their doors or restricted service territory to reduce care costs.” Shortly after CMS released its 5.1% proposal in July, the NAHC petitioned the U.S. District Court for the District of Columbia to strike down and vacate the home health prospective payment system final rule, and to withhold apply the 2024 proposal, saying Congress would prohibit the pay cuts for causing "substantial financial harm" to home health agencies under the Bipartisan Budget Act of 2018. Other changes include increasing the CY 2024 home health market basket percentage by 3.3% before adjusting the rate by 0.3% to 3.0%, a finalized labor related share of 74.9% and non-labor-related share of 25.1% and codify a $270.09 payment toward home health purchases for disposable negative pressure wound therapy (dNPWT) devices. “The actions CMS is taking in this final rule will help improve patient care and also protect the Medicare program’s sustainability for future generations,” CMS said in a release. Wednesday’s rule drop included modifications to the Home Health (HH) Quality Reporting Program (QRP) as well, removing the Application of Percent of Long-Term Care Hospital (LTCH) Patients with an Admission and Discharge Functional Assessment beginning in CY 2025. It also removed two Outcome and Assessment Information Set (OASIS) items no longer necessary for collection. Additionally, home health agencies must meet a 90% threshold of all required OASIS items. Changes under the HH QRP is estimated to reduce cost by more than $5M by reducing unnecessary data collection. The Home Healthy Value-Based Purchasing (HHVBP) Model will codify the measure removal factors finalized in the CY 2022 final rule, replace the claims-based Acute Care Hospitalization During the First 60 Days of Home Health Use measures with the Potentially Preventable Hospitalization measure, effective Jan. 1, 2025, according to the release. “The overall economic impact of the expanded HHVBP Model for CYs 2024 through 2027 is an estimated $3.376 billion in total savings to FFS Medicare from a reduction in unnecessary hospitalizations and SNF usage as a result of greater quality improvements in the HH industry,” the rule said. Permanent coverage and payment of items related to IVIG (Medicare Intravenous Immune Globulin) for patients at home with a primary immune deficiency disease was finalized, now that the Medicare Demonstration program will cease payment using the average sales price (ASP) methodology at the end of the year. This should account for an increase in $8.7 million in total costs to traditional Medicare plans. Under the new rules, Medicare Part B will have an expanded definition for identifying lymphedema treatment that is covered. CMS also finalized plans that codify documentation requirements for Durable Medical Equipment, Prosthetics, Orthotics, & Supplies (DMEPOS) refills. “For the conforming change to sections in CAA of 2023 provision, the overall economic impact for CY 2023 and CY 2024 is an estimated $100 million in total cost to FFS Medicare,” the rule said. “For the lymphedema provision, the overall economic impact for CYs 2023 to 2028 is an estimated $150 million in total cost to FFS Medicare.”

AHA

100 Deals associated with Immune Globulin Intravenous (Human) (Octapharma)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	United States	Octapharma Pharmazeutika Produktionsgesellschaft Mbh	02 Aug 2018
Immunologic Deficiency Syndromes	Canada	Octapharma Pharmazeutika Produktionsgesellschaft Mbh	15 Feb 2018
Acquired Immunodeficiency Syndrome	Australia	Octapharma AG	11 Nov 2009
Agammaglobulinemia	Australia	Octapharma AG	11 Nov 2009
Chronic Lymphocytic Leukemia	Australia	Octapharma AG	11 Nov 2009
Common Variable Immunodeficiency	Australia	Octapharma AG	11 Nov 2009
Guillain-Barre Syndrome	Australia	Octapharma AG	11 Nov 2009
Hypogammaglobulinemia	Australia	Octapharma AG	11 Nov 2009
Mucocutaneous Lymph Node Syndrome	Australia	Octapharma AG	11 Nov 2009
Primary Immunodeficiency Diseases	Australia	Octapharma AG	11 Nov 2009
Severe Combined Immunodeficiency	Australia	Octapharma AG	11 Nov 2009
Wiskott-Aldrich Syndrome	Australia	Octapharma AG	11 Nov 2009
Dermatomyositis	United States	Octapharma Pharmazeutika Produktionsgesellschaft Mbh	21 May 2004
Purpura, Thrombocytopenic, Idiopathic	United States	Octapharma Pharmazeutika Produktionsgesellschaft Mbh	21 May 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pediatric Acute-Onset Neuropsychiatric Syndrome	Phase 3	United States	Octapharma AG	30 Jun 2021
Pediatric Acute-Onset Neuropsychiatric Syndrome	Phase 3	Italy	Octapharma AG	30 Jun 2021
Pediatric Acute-Onset Neuropsychiatric Syndrome	Phase 3	Sweden	Octapharma AG	30 Jun 2021
Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections	Phase 3	United States	Octapharma AG	30 Jun 2021
Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections	Phase 3	Italy	Octapharma AG	30 Jun 2021
Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections	Phase 3	Sweden	Octapharma AG	30 Jun 2021
Recurrent Chronic Lymphoid Leukemia	Phase 3	United States	Octapharma AG	05 Oct 2020
Recurrent Chronic Lymphoid Leukemia	Phase 3	Czechia	Octapharma AG	05 Oct 2020
Recurrent Chronic Lymphoid Leukemia	Phase 3	Denmark	Octapharma AG	05 Oct 2020
Recurrent Chronic Lymphoid Leukemia	Phase 3	Germany	Octapharma AG	05 Oct 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03866798 (CTgov)	Phase 4	Purpura, Thrombocytopenic, Idiopathic	6	Panzyga	xztuijmgvs = gzwbkeikgs kyspedemyu (dwngnvukfx, etscbmcbfy - qlpozlhxlb) View more	-	07 Aug 2024
NCT03939533 (CTgov)	Phase 3	Primary Immunodeficiency Diseases	64	CUTAQUIG (Increased Volume Cohort - Cohort 1)	asmxuxzheg(elseagdwka) = wlumdllngl kzifknxjte (gnomeynayu, 0.7303) View more	-	07 Nov 2023
				CUTAQUIG (Increased Infusion Rate Cohort - Cohort 2)	asmxuxzheg(elseagdwka) = kiisqipxow kzifknxjte (gnomeynayu, 1.1046) View more
NCT02728752 (ProDERM, Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	Dermatomyositis	95	Intravenous Immune Globulin	pcnvenpphn(xpgjiqrqpj) = xnmrcgqliz jtykbtxmcq (ujlrqwsnbp )	Positive	06 Oct 2022
				Placebo	pcnvenpphn(xpgjiqrqpj) = ucadwrogrj jtykbtxmcq (ujlrqwsnbp )
NCT03686969 (SCGAM-02, CTgov)	Phase 3	Dermatomyositis	1	Octanorm (Octanorm)	eszfxlpnxa(qmgtuipbkd) = vxtutapjgf satzxofjgc (uybugmwmaj, ntquuwurkq - edvehgzxfi) View more	-	23 Apr 2021
				Placebo (Placebo)	eszfxlpnxa(qmgtuipbkd) = bqwdifrfrl satzxofjgc (uybugmwmaj, kbqvuambpg - wemjvmcmgc) View more
NCT02728752 (ProDERM \| ProDERM Study \| IIM, CTgov)	Phase 3	Idiopathic Inflammatory Myopathies \| Dermatomyositis	95	Placebo (Placebo)	jsljnczewl = yibzgzsxnu pksyqmasxl (ryngtbgicf, asoptiahiy - vqmrnjcjaj) View more	-	21 Apr 2021
				Octagam 10% (Octagam10%)	jsljnczewl = gbyeyirgme pksyqmasxl (ryngtbgicf, advkcnmejd - sifjjffliq) View more
NCT02638207 (ProCID \| CIDP, CTgov)	Phase 3	Multifocal acquired demyelinating sensory and motor neuropathy \| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	142	NewGam (1.0 g/kg NewGam)	vjbqqkoabn = yfglfmbuzp uygvqczxru (qlmbgwmhhw, esxhguvkhi - cnswsoofak) View more	-	16 Feb 2021
				NewGam (0.5 g/kg NewGam)	fdvhjsfdmn = levrovwnyz xekeidgyiw (uaeechwkrl, ecnkbmejzl - ljewfhzdgw) View more
NCT02728752 (ProDERM Study, ACR2020) Manual	Phase 3	-	95	Octagam 10%	wcmzshqizo(vodxpnpigm) = xmddyaxxgi xferoyfhfv (mjnnonsbad ) View more	Positive	07 Nov 2020
				Placebo	wcmzshqizo(vodxpnpigm) = funuvkklmp xferoyfhfv (mjnnonsbad ) View more
NCT03319810 (CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	5	Octagam 10%	bnqdymcxey(jnuorqdjrz) = tjzmfrcynr gfykrrcaco (bibzfyqxhj, 2.84) View more	-	16 Apr 2019
NCT00811174 (CTgov)	Phase 3	Primary Immunodeficiency Diseases	5	Octagam 10%	pomcwkjkzj = dyqbizyomh mhcehbezdv (mimxzdelmj, skqpmeunwn - dicwmioymq) View more	-	14 Jul 2017
NCT01349790 (CTgov)	Phase 3	Purpura, Thrombocytopenic, Idiopathic \| Primary thrombocytopenia	40	NewGam	rrzfzzcidx = cazlkjifpp lgatixwdnz (qyutdctiuq, nhamsjqeat - kgrflnxlsr) View more	-	07 Jun 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Immune Globulin Intravenous (Human) (Octapharma)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation